Stock Rich List
#11066 on the rich list of 14,644 insiders

John P. Schmid

Director at AnaptysBio; Director at Xeris Biopharma Holdings; Director at First Tracks Biotherapeutics. Based in San Diego, California.

$7.3M
in disclosed stock, −$44K (−0.59%) today
Market closed. Prices as of Nov 19, 4:00 PM ET
Rank
11066th of 14,644
Companies held
6
Largest holding
ANAB, 35.2% of total
Latest SEC filing
Aug 10, 2026

What the $7.3M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Xeris Biopharma Holdings XERS
Common Stock
Directly113,159$16.62$1.9M25.7%Form 4, Aug 12, 2024
AnaptysBio ANAB
Common Stock
Directly37,652$47.40$1.8M24.4%Form 4, Jun 15, 2026
First Tracks Biotherapeutics TRAX
Common Stock
Directly37,652$44.46$1.7M22.9%Form 4, Jun 15, 2026
AnaptysBio ANAB
Common Stock
Through ESOP16,602
split-adjusted
$47.40$787K10.8%Form 4, Jun 15, 2025
Xeris Biopharma Holdings XERS
Common Stock
By: The Schmid Family Trust dated August 15, 201725,200$16.62$419K5.7%Form 4, Aug 12, 2024
Design Therapeutics DSGN
Common Stock
Directly30,674$9.32$286K3.9%Form 4, Mar 22, 2024
Design Therapeutics DSGN
Common Stock
Through Schmid Family Trust U/A dated 8-15-1726,965$9.32$251K3.4%Form 4, Mar 25, 2024
BlossomHill Therapeutics BLSM
Common Stock
Directly6,000$14.41$86K1.2%Form 4, Aug 10, 2026
Design Therapeutics DSGN
Common Stock
Through Schmid Family Trust U/A dated 8-15-179,156$9.32$85K1.2%Form 4, Mar 22, 2024
BridgeBio Oncology Therapeutics BBOT
Common Stock
Directly30,000$1.86$56K0.8%Form 4, Aug 11, 2025

Share counts are the amounts John P. Schmid reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Aug 10, 2026BoughtBLSM6,000$16.00$96KView
Mar 30, 2026SoldANAB12,596$55.71$702KView
Mar 30, 2026SoldANAB7,527$56.70$427KView
Mar 30, 2026SoldANAB522$57.40$30KView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
11063Daniel J. Phelan
Director, TE Connectivity. Berwyn, PA
$7.3M−$32K (−0.43%)
11064Anthony M. Santomero
Director, RenaissanceRe Holdings
$7.3M−$67K (−0.91%)
11065Gregory C. Toczydlowski
EVP & President, Business Ins., The Travelers Companies. St. Paul, MN
$7.3M−$14K (−0.20%)
11066John P. Schmid
Director, AnaptysBio. San Diego, CA
$7.3M−$44K (−0.59%)
11067Thomas C. Popeck
CEO, Henry Schein Products, Henry Schein. Melville, NY
$7.3M−$77K (−1.04%)
11068Melissa Werneck
EVP & Global Chief People Ofcr, The Kraft Heinz. Charlotte, NC
$7.3M−$143K (−1.92%)
11069David W. Osborne
Chief Technical Officer, Arcutis Biotherapeutics. Westlake Village, CA
$7.3M−$118K (−1.59%)

Other AnaptysBio insiders

All ANAB insiders

Questions

How much stock does John P. Schmid own?

John P. Schmid holds $7,309,963 in listed stock based on SEC filings and current prices, mostly Xeris Biopharma Holdings (XERS). That ranks 11066th on the Stock Rich List.

Is this John P. Schmid's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did John P. Schmid last buy or sell stock?

The most recent open-market trade on file is a purchase of 6,000 BLSM shares on Aug 10, 2026 at $16.00.